Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Insight and Resources From a Study of the "Impact of Sex, Androgens, and Prostate Size on C57BL/6J Mouse Urinary Physiology.

Ruetten H, Wegner KA, Zhang HL, Wang P, Sandhu J, Sandhu S, Morkrid J, Mueller B, Wang Z, Macoska J, Peterson RE, Bjorling DE, Ricke WA, Marker PC, Vezina CM.

Toxicol Pathol. 2019 Oct 29:192623319877867. doi: 10.1177/0192623319877867. [Epub ahead of print]

PMID:
31662055
2.

Reproductive tract biology: Of mice and men.

Cunha GR, Sinclair A, Ricke WA, Robboy SJ, Cao M, Baskin LS.

Differentiation. 2019 Sep 6;110:49-63. doi: 10.1016/j.diff.2019.07.004. [Epub ahead of print] Review.

PMID:
31622789
3.

Incidence of androgen receptor and androgen receptor variant 7 coexpression in prostate cancer.

Vellky JE, Bauman TM, Ricke EA, Huang W, Ricke WA.

Prostate. 2019 Dec;79(16):1811-1822. doi: 10.1002/pros.23906. Epub 2019 Sep 10.

PMID:
31503366
4.

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing.

Liu TT, Rodgers AC, Nicholson TM, Macoska JA, Marker PC, Vezina CM, Bjorling DE, Roldan-Alzate A, Hernando D, Lloyd GL, Hacker TA, Ricke WA.

J Vis Exp. 2019 Aug 14;(150). doi: 10.3791/59802.

PMID:
31475976
5.

Estrogen receptor 1 expression and methylation of Esr1 promoter in mouse fetal prostate mesenchymal cells induced by gestational exposure to bisphenol A or ethinylestradiol.

Bhandari RK, Taylor JA, Sommerfeld-Sager J, Tillitt DE, Ricke WA, Vom Saal FS.

Environ Epigenet. 2019 Aug 22;5(3):dvz012. doi: 10.1093/eep/dvz012. eCollection 2019 Jul.

6.

Impact of sex, androgens, and prostate size on C57BL/6J mouse urinary physiology: functional assessment.

Ruetten H, Wegner KA, Zhang HL, Wang P, Sandhu J, Sandhu S, Mueller B, Wang Z, Macoska J, Peterson RE, Bjorling DE, Ricke WA, Marker PC, Vezina CM.

Am J Physiol Renal Physiol. 2019 Oct 1;317(4):F996-F1009. doi: 10.1152/ajprenal.00270.2019. Epub 2019 Aug 7.

PMID:
31390231
7.

Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?

Lloyd GL, Marks JM, Ricke WA.

Curr Urol Rep. 2019 Aug 3;20(9):54. doi: 10.1007/s11934-019-0917-1. Review.

PMID:
31377881
8.

Void sorcerer: an open source, open access framework for mouse uroflowmetry.

Wang Z, Guzman EC, Nimunkar A, Keil KP, Vezina CM, Ricke WA, Macoska J, Bjorling DE.

Am J Clin Exp Urol. 2019 Jun 15;7(3):170-177. eCollection 2019.

9.

MRI-based method for lower urinary tract dysfunction in adult male mice.

McLean DT, Rutkowski DR, Liu T, Hernando D, Ricke WA, Roldán-Alzate A.

Am J Clin Exp Urol. 2019 Jun 15;7(3):153-158. eCollection 2019.

10.

Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study.

Macoska JA, Uchtmann KS, Leverson GE, McVary KT, Ricke WA.

J Urol. 2019 Dec;202(6):1240-1247. doi: 10.1097/JU.0000000000000385. Epub 2019 Jun 12.

PMID:
31188728
11.

Expression and distribution of PIEZO1 in the mouse urinary tract.

Dalghi MG, Clayton DR, Ruiz WG, Al-Bataineh MM, Satlin LM, Kleyman TR, Ricke WA, Carattino MD, Apodaca G.

Am J Physiol Renal Physiol. 2019 Aug 1;317(2):F303-F321. doi: 10.1152/ajprenal.00214.2019. Epub 2019 Jun 5.

PMID:
31166705
12.

Prostate enlargement and altered urinary function are part of the aging process.

Liu TT, Thomas S, Mclean DT, Roldan-Alzate A, Hernando D, Ricke EA, Ricke WA.

Aging (Albany NY). 2019 May 13;11(9):2653-2669. doi: 10.18632/aging.101938.

13.

Tissue-specific quantification and localization of androgen and estrogen receptors in prostate cancer.

Sehgal PD, Bauman TM, Nicholson TM, Vellky JE, Ricke EA, Tang W, Xu W, Huang W, Ricke WA.

Hum Pathol. 2019 Jul;89:99-108. doi: 10.1016/j.humpath.2019.04.009. Epub 2019 May 3.

PMID:
31054895
14.

Quantitative proteomic analysis of a genetically induced prostate inflammation mouse model via custom 4-plex DiLeu isobaric labeling.

Hao L, Thomas S, Greer T, Vezina CM, Bajpai S, Ashok A, De Marzo AM, Bieberich CJ, Li L, Ricke WA.

Am J Physiol Renal Physiol. 2019 Jun 1;316(6):F1236-F1243. doi: 10.1152/ajprenal.00387.2018. Epub 2019 Apr 17.

PMID:
30995113
15.

Expression and Localization of DDX3 in Prostate Cancer Progression and Metastasis.

Vellky JE, Ricke EA, Huang W, Ricke WA.

Am J Pathol. 2019 Jun;189(6):1256-1267. doi: 10.1016/j.ajpath.2019.02.011. Epub 2019 Mar 27.

PMID:
30926334
16.

Comprehensive urinary metabolomic characterization of a genetically induced mouse model of prostatic inflammation.

Hao L, Shi Y, Thomas S, Vezina CM, Bajpai S, Ashok A, Bieberich CJ, Ricke WA, Li L.

Int J Mass Spectrom. 2018 Nov;434:185-192. doi: 10.1016/j.ijms.2018.09.017. Epub 2018 Sep 22.

17.

Targeting a fibrotic bottleneck may provide an opening in the treatment of LUTS.

Ricke WA, Bruskewitz RC, Liu TT.

Am J Physiol Renal Physiol. 2019 Jun 1;316(6):F1091-F1093. doi: 10.1152/ajprenal.00102.2019. Epub 2019 Mar 13. No abstract available.

PMID:
30864837
18.

Inflammation, Voiding and Benign Prostatic Hyperplasia Progression.

Lloyd GL, Ricke WA, McVary KT.

J Urol. 2019 May;201(5):868-870. doi: 10.1097/JU.0000000000000049. No abstract available.

PMID:
30694937
19.

Modeling human prostate cancer progression in vitro.

Liu TT, Ewald JA, Ricke EA, Bell R, Collins C, Ricke WA.

Carcinogenesis. 2019 Jul 20;40(7):893-902. doi: 10.1093/carcin/bgy185.

PMID:
30590461
20.

Development of the human prostate.

Cunha GR, Vezina CM, Isaacson D, Ricke WA, Timms BG, Cao M, Franco O, Baskin LS.

Differentiation. 2018 Sep - Oct;103:24-45. doi: 10.1016/j.diff.2018.08.005. Epub 2018 Sep 4. Review.

21.

Endocrine disruptor bisphenol A is implicated in urinary voiding dysfunction in male mice.

Nicholson TM, Nguyen JL, Leverson GE, Taylor JA, Vom Saal FS, Wood RW, Ricke WA.

Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1208-F1216. doi: 10.1152/ajprenal.00582.2017. Epub 2018 Jul 18.

22.

Void spot assay procedural optimization and software for rapid and objective quantification of rodent voiding function, including overlapping urine spots.

Wegner KA, Abler LL, Oakes SR, Mehta GS, Ritter KE, Hill WG, Zwaans BM, Lamb LE, Wang Z, Bjorling DE, Ricke WA, Macoska J, Marker PC, Southard-Smith EM, Eliceiri KW, Vezina CM.

Am J Physiol Renal Physiol. 2018 Oct 1;315(4):F1067-F1080. doi: 10.1152/ajprenal.00245.2018. Epub 2018 Jul 4.

23.

Prostate cancer xenografts and hormone induced prostate carcinogenesis.

McLean DT, Strand DW, Ricke WA.

Differentiation. 2017 Sep - Oct;97:23-32. doi: 10.1016/j.diff.2017.08.005. Epub 2017 Sep 8. Review.

24.

Targeting phenotypic heterogeneity in benign prostatic hyperplasia.

Strand DW, Costa DN, Francis F, Ricke WA, Roehrborn CG.

Differentiation. 2017 Jul - Aug;96:49-61. doi: 10.1016/j.diff.2017.07.005. Epub 2017 Aug 4. Review.

25.

In-Depth Characterization and Validation of Human Urine Metabolomes Reveal Novel Metabolic Signatures of Lower Urinary Tract Symptoms.

Hao L, Greer T, Page D, Shi Y, Vezina CM, Macoska JA, Marker PC, Bjorling DE, Bushman W, Ricke WA, Li L.

Sci Rep. 2016 Aug 9;6:30869. doi: 10.1038/srep30869.

26.

Comparison of Picrosirius Red Staining With Second Harmonic Generation Imaging for the Quantification of Clinically Relevant Collagen Fiber Features in Histopathology Samples.

Drifka CR, Loeffler AG, Mathewson K, Mehta G, Keikhosravi A, Liu Y, Lemancik S, Ricke WA, Weber SM, Kao WJ, Eliceiri KW.

J Histochem Cytochem. 2016 Sep;64(9):519-29. doi: 10.1369/0022155416659249. Epub 2016 Jul 22.

27.

Opposing Effects of Cyclooxygenase-2 (COX-2) on Estrogen Receptor β (ERβ) Response to 5α-Reductase Inhibition in Prostate Epithelial Cells.

Liu TT, Grubisha MJ, Frahm KA, Wendell SG, Liu J, Ricke WA, Auchus RJ, DeFranco DB.

J Biol Chem. 2016 Jul 8;291(28):14747-60. doi: 10.1074/jbc.M115.711515. Epub 2016 May 13.

28.

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging.

Bauman TM, Ricke EA, Drew SA, Huang W, Ricke WA.

J Vis Exp. 2016 Apr 8;(110). doi: 10.3791/53837.

29.

Monohaloacetic acid drinking water disinfection by-products inhibit follicle growth and steroidogenesis in mouse ovarian antral follicles in vitro.

Jeong CH, Gao L, Dettro T, Wagner ED, Ricke WA, Plewa MJ, Flaws JA.

Reprod Toxicol. 2016 Jul;62:71-6. doi: 10.1016/j.reprotox.2016.04.028. Epub 2016 May 2.

30.

Expression and colocalization of β-catenin and lymphoid enhancing factor-1 in prostate cancer progression.

Bauman TM, Vezina CM, Ricke EA, Halberg RB, Huang W, Peterson RE, Ricke WA.

Hum Pathol. 2016 May;51:124-33. doi: 10.1016/j.humpath.2015.12.024. Epub 2016 Jan 19.

31.

In Utero and Lactational TCDD Exposure Increases Susceptibility to Lower Urinary Tract Dysfunction in Adulthood.

Ricke WA, Lee CW, Clapper TR, Schneider AJ, Moore RW, Keil KP, Abler LL, Wynder JL, López Alvarado A, Beaubrun I, Vo J, Bauman TM, Ricke EA, Peterson RE, Vezina CM.

Toxicol Sci. 2016 Apr;150(2):429-40. doi: 10.1093/toxsci/kfw009. Epub 2016 Feb 9.

32.

Biomarker discovery in mass spectrometry-based urinary proteomics.

Thomas S, Hao L, Ricke WA, Li L.

Proteomics Clin Appl. 2016 Apr;10(4):358-70. doi: 10.1002/prca.201500102. Epub 2016 Feb 11. Review.

33.

SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.

Bauman TM, Becka AJ, Sehgal PD, Huang W, Ricke WA.

Hum Pathol. 2015 Nov;46(11):1744-51. doi: 10.1016/j.humpath.2015.07.015. Epub 2015 Jul 29.

34.

Custom 4-Plex DiLeu Isobaric Labels Enable Relative Quantification of Urinary Proteins in Men with Lower Urinary Tract Symptoms (LUTS).

Greer T, Hao L, Nechyporenko A, Lee S, Vezina CM, Ricke WA, Marker PC, Bjorling DE, Bushman W, Li L.

PLoS One. 2015 Aug 12;10(8):e0135415. doi: 10.1371/journal.pone.0135415. eCollection 2015.

35.

CD147 expression predicts biochemical recurrence after prostatectomy independent of histologic and pathologic features.

Bauman TM, Ewald JA, Huang W, Ricke WA.

BMC Cancer. 2015 Jul 25;15:549. doi: 10.1186/s12885-015-1559-4.

36.

Estrogens and Male Lower Urinary Tract Dysfunction.

Wynder JL, Nicholson TM, DeFranco DB, Ricke WA.

Curr Urol Rep. 2015 Sep;16(9):61. doi: 10.1007/s11934-015-0534-6. Review.

37.

Evaluation of voiding assays in mice: impact of genetic strains and sex.

Bjorling DE, Wang Z, Vezina CM, Ricke WA, Keil KP, Yu W, Guo L, Zeidel ML, Hill WG.

Am J Physiol Renal Physiol. 2015 Jun 15;308(12):F1369-78. doi: 10.1152/ajprenal.00072.2015. Epub 2015 Apr 22.

38.

Impact of a folic acid-enriched diet on urinary tract function in mice treated with testosterone and estradiol.

Keil KP, Abler LL, Altmann HM, Wang Z, Wang P, Ricke WA, Bjorling DE, Vezina CM.

Am J Physiol Renal Physiol. 2015 Jun 15;308(12):F1431-43. doi: 10.1152/ajprenal.00674.2014. Epub 2015 Apr 8.

39.

Microfluidic multiculture assay to analyze biomolecular signaling in angiogenesis.

Theberge AB, Yu J, Young EW, Ricke WA, Bushman W, Beebe DJ.

Anal Chem. 2015 Mar 17;87(6):3239-46. doi: 10.1021/ac503700f. Epub 2015 Feb 26.

40.

Beta-catenin is elevated in human benign prostatic hyperplasia specimens compared to histologically normal prostate tissue.

Bauman TM, Vezina CM, Huang W, Marker PC, Peterson RE, Ricke WA.

Am J Clin Exp Urol. 2014 Dec 25;2(4):313-22. eCollection 2014.

41.

The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.

Moses MA, Henry EC, Ricke WA, Gasiewicz TA.

Cancer Prev Res (Phila). 2015 Mar;8(3):249-57. doi: 10.1158/1940-6207.CAPR-14-0224. Epub 2015 Jan 20.

42.

Influence of animal husbandry practices on void spot assay outcomes in C57BL/6J male mice.

Keil KP, Abler LL, Altmann HM, Bushman W, Marker PC, Li L, Ricke WA, Bjorling DE, Vezina CM.

Neurourol Urodyn. 2016 Feb;35(2):192-8. doi: 10.1002/nau.22692. Epub 2014 Nov 12.

43.

Characterization of fibrillar collagens and extracellular matrix of glandular benign prostatic hyperplasia nodules.

Bauman TM, Nicholson TM, Abler LL, Eliceiri KW, Huang W, Vezina CM, Ricke WA.

PLoS One. 2014 Oct 2;9(10):e109102. doi: 10.1371/journal.pone.0109102. eCollection 2014.

44.

Estrogen receptor-α is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia.

Nicholson TM, Moses MA, Uchtmann KS, Keil KP, Bjorling DE, Vezina CM, Wood RW, Ricke WA.

J Urol. 2015 Feb;193(2):722-9. doi: 10.1016/j.juro.2014.08.093. Epub 2014 Aug 25.

45.

Bisphenol a and reproductive health: update of experimental and human evidence, 2007-2013.

Peretz J, Vrooman L, Ricke WA, Hunt PA, Ehrlich S, Hauser R, Padmanabhan V, Taylor HS, Swan SH, VandeVoort CA, Flaws JA.

Environ Health Perspect. 2014 Aug;122(8):775-86. doi: 10.1289/ehp.1307728. Epub 2014 Jun 4. Review.

46.

Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues.

Bauman TM, Sehgal PD, Johnson KA, Pier T, Bruskewitz RC, Ricke WA, Huang W.

Prostate. 2014 Jun;74(9):923-32. doi: 10.1002/pros.22810. Epub 2014 Apr 30.

47.

Steroidogenic factor 1 promotes aggressive growth of castration-resistant prostate cancer cells by stimulating steroid synthesis and cell proliferation.

Lewis SR, Hedman CJ, Ziegler T, Ricke WA, Jorgensen JS.

Endocrinology. 2014 Feb;155(2):358-69. doi: 10.1210/en.2013-1583. Epub 2013 Nov 21.

48.

Renal capsule xenografting and subcutaneous pellet implantation for the evaluation of prostate carcinogenesis and benign prostatic hyperplasia.

Nicholson TM, Uchtmann KS, Valdez CD, Theberge AB, Miralem T, Ricke WA.

J Vis Exp. 2013 Aug 28;(78). doi: 10.3791/50574.

49.

Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.

Nicholson TM, Sehgal PD, Drew SA, Huang W, Ricke WA.

Differentiation. 2013 Apr-Jun;85(4-5):140-9. doi: 10.1016/j.diff.2013.02.006. Epub 2013 Jun 20.

50.

Expression microarray meta-analysis identifies genes associated with Ras/MAPK and related pathways in progression of muscle-invasive bladder transition cell carcinoma.

Ewald JA, Downs TM, Cetnar JP, Ricke WA.

PLoS One. 2013;8(2):e55414. doi: 10.1371/journal.pone.0055414. Epub 2013 Feb 1.

Supplemental Content

Loading ...
Support Center